# Nuclide record advanced-accelerator-applications (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/advanced-accelerator-applications/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "advanced-accelerator-applications" ;
  schema:name "Advanced Accelerator Applications (Novartis)"@en ;
  schema:description "The CERN spin-out that Novartis bought in 2018 for Lutathera, which now makes Pluvicto and the Locametz and Netspot imaging kits."@en ;
  schema:url <https://nuclide.cc/companies/advanced-accelerator-applications/>, <https://www.adacap.com> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.adacap.com> ;
  schema:addressCountry "FR" ;
  nuclide:related <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/neuroendocrine/> ;
  nuclide:technologies <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/technologies/sstr-pet/>, <https://nuclide.cc/technologies/radioligand-therapy/> ;
  nuclide:drugs <https://nuclide.cc/drugs/locametz/>, <https://nuclide.cc/drugs/ga68-dotatate/>, <https://nuclide.cc/drugs/pluvicto/> ;
  nuclide:companies <https://nuclide.cc/companies/novartis/> ;
  nuclide:trials <https://nuclide.cc/trials/nct05849298/>, <https://nuclide.cc/trials/nct07047118/>, <https://nuclide.cc/trials/nct06784752/>, <https://nuclide.cc/trials/nct04939610/>, <https://nuclide.cc/trials/nct05658003/>, <https://nuclide.cc/trials/nct03972488/>, <https://nuclide.cc/trials/nct06247995/> .